STAR — Strides Pharma Science Balance Sheet
0.000.00%
- IN₹61.14bn
- IN₹80.31bn
- IN₹40.51bn
- 80
- 39
- 97
- 86
Annual balance sheet for Strides Pharma Science, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 3,474 | 2,749 | 1,842 | 3,607 | 2,896 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 10,816 | 12,454 | 18,898 | 15,005 | 14,024 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 23,721 | 28,172 | 33,618 | 32,434 | 29,690 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 14,639 | 14,994 | 15,136 | 13,726 | 9,585 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 61,517 | 70,150 | 69,759 | 66,384 | 58,398 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 25,449 | 27,383 | 34,117 | 29,902 | 28,793 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 36,243 | 42,384 | 46,166 | 44,262 | 37,142 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 25,274 | 27,767 | 23,592 | 22,123 | 21,256 |
Total Liabilities & Shareholders' Equity | 61,517 | 70,150 | 69,759 | 66,384 | 58,398 |
Total Common Shares Outstanding |